CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis.
Lisa MasucciFeng TianStephen TullyZeny FengThomas McFarlaneKelvin Kar-Wing ChanWilliam W L WongPublished in: Medical decision making : an international journal of the Society for Medical Decision Making (2024)
For patients with diffuse large B-cell lymphoma who failed 2 or more lines of systemic therapy, CAR T was not found to be a cost-effective treatment option at a willingness-to-pay threshold of $100,000.These results heavily depend on the expected long-term survival. The uncertainty in the model may be improved using real-world evidence reported in the future.